Mirae Asset Global Investments Co., Ltd. Corbus Pharmaceuticals Holdings, Inc. Transaction History

Mirae Asset Global Investments Co., Ltd.

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 10, 2022	SELL	$0.17 - $5.31 $617,138 - $19.3 Million	-3,630,226 Reduced 90.1%	398,945 $66,000
Q2 2022 Jul 26, 2022	BUY	$0.21 - $0.53 $57,585 - $145,335	274,217 Added 7.3%	4,029,171 $1.02 Million
Q1 2022 May 10, 2022	SELL	$0.32 - $0.67 $100,816 - $211,084	-315,052 Reduced 7.74%	3,754,954 $2 Million
Q4 2021 Feb 08, 2022	BUY	$0.6 - $1.11 $41,861 - $77,443	69,769 Added 1.74%	4,070,006 $2.51 Million
Q3 2021 Nov 15, 2021	SELL	$1.01 - $1.82 $898,227 - $1.62 Million	-889,334 Reduced 18.19%	4,000,237 $4.08 Million
Q2 2021 Aug 11, 2021	BUY	$1.39 - $2.21 $2.08 Million - $3.3 Million	1,493,178 Added 43.96%	4,889,571 $8.95 Million
Q1 2021 May 13, 2021	BUY	$1.27 - $3.42 $1.71 Million - $4.6 Million	1,346,291 Added 65.67%	3,396,393 $6.69 Million
Q4 2020 Feb 10, 2021	BUY	$0.94 - $1.89 $1.1 Million - $2.21 Million	1,170,507 Added 133.07%	2,050,102 $2.56 Million
Q3 2020 Nov 12, 2020	BUY	$1.5 - $9.38 $214,960 - $1.34 Million	143,307 Added 19.46%	879,595 $1.58 Million
Q2 2020 Aug 11, 2020	BUY	$4.79 - $8.39 $334,696 - $586,242	69,874 Added 10.49%	736,288 $6.18 Million
Q1 2020 May 12, 2020	BUY	$3.44 - $7.21 $34,654 - $72,633	10,074 Added 1.53%	666,414 $3.49 Million
Q4 2019 Feb 12, 2020	SELL	$4.29 - $5.64 $2.02 Million - $2.65 Million	-470,472 Reduced 41.75%	656,340 $3.59 Million
Q3 2019 Nov 12, 2019	BUY	$4.87 - $7.08 $251,496 - $365,625	51,642 Added 4.8%	1,126,812 $5.49 Million
Q2 2019 Aug 13, 2019	BUY	$6.6 - $7.8 $7.1 Million - $8.39 Million	1,075,170 New	1,075,170 $7.45 Million

38.7K

Ticker CRBP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 125,268,000
Market Cap $2.08B
Description
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an...

Get notified when there are updates to the investment portfolio of Mirae Asset Global Investments Co., Ltd., based on Form 13F filings with the SEC.

Stay updated on Mirae Asset Global Investments Co., Ltd. with notifications on news.